Drugs / rhIFN beta-1b
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01464905 Comparator | Oct 2011 → Dec 2013 | relapsing-remitting multiple sclerosis | Nuron Biotech Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhIFN beta-1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01464905 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human interferon beta- 1b” NCT01464905 ↗ |
| Route | Subcutaneous | “0.25 mg SQ, every other day for 12 months” NCT01464905 ↗ |